LncMAPK6 drives MAPK6 expression and liver TIC self-renewal

Guanqun Huang†, Hui Jiang‡, Yueming He‡, Ye Lin³, Wuzheng Xia³, Yuanwei Luo¹, Min Liang², Boyun Shi², Xinke Zhou²∗ and Zhixiang Jian³∗

Abstract

Background: Liver tumor initiating cells (TICs) have self-renewal and differentiate capacities, and largely contribute to tumor initiation, metastasis and drug resistance. MAPK signaling is a critical pathway in many biological processes, while its role in liver TICs hasn’t been explored.

Methods: Online-available dataset was used for unbiased screening. Liver TICs were examined CD133 FACS or oncosphere formation. TIC self-renewal was detected by oncosphere formation and tumor initiation assay. LncRNA function was detected by loss of function or gain of function assays. The molecular mechanism of LncRNA was explored by RNA pulldown, RNA immunoprecipitation, ChiP, western blot and double FISH.

Results: Here, we examined the expression profiles of MAPK components (MAPKs, MAP2Ks, MAP3Ks, MAP4Ks), and found MAPK6 is most highly expressed in liver cancer samples. Moreover, a divergent lncRNA (long noncoding RNA) of MAPK6, termed LncMAPK6 here, is also overexpressed along with liver tumorigenesis. LncMAPK6 promotes liver tumor propagation and TIC self-renewal through MAPK6. LncMAPK6 interacts with and recruits RNA polymerase II to MAPK6 promoter, and finally activates the transcription of MAPK6. Through MAPK6 transcriptional regulation, LncMAPK6 drives MARK signaling activation. LncMAPK6-MARK6 pathway can be used for liver TIC targeting. Altogether, LncMAPK6 promotes MARK signaling and the self-renewal of liver TICs through MAPK6 expression.

Conclusion: MAPK6 was the most highly expressed MAPK component in liver cancer and liver TICs and LncMAPK6 participated in the transcriptional regulation of MAPK6 in cis. This work revealed the importance role of MAPK signaling in liver TIC self-renewal and added a new layer for liver TIC and MAPK6 expression regulation.

Keywords: MAPK6, LncMAPK6, Liver TIC, Self-renewal, Tumor targeting
and development [14, 20, 28, 44]. However, the role of MAPK signaling pathway in liver TICs hasn’t been explored. Here we performed an unbiased screening on the expression profile of MAPK components in liver tumorigenesis, and found MAPK6 (mitogen-activated protein kinase 6) was the most highly expressed MAPK component in liver cancer and liver TICs.

MAPK6 is a member of the Ser/Thr protein kinase family and also termed as Erk3. MAPK6 is related to Arrhythmogenic right ventricular cardiomyopathy (ARVC) and p70S6K Signaling, and associates with pulmonary immaturity [3, 19]. It is known that MARK6 can be phosphorylated at ser-189 and then activate MARKAPK5, which in turn phosphorylates MARK6 [2]. By similarity, MAPK6 may promote cell cycle entrance. As for tumorigenesis, MARP6 participates in HCC development and non-small-cell lung cancer (NSCLC) development [5, 6]. While, its role in liver TICs is unclear. Here we found MAPK6 is vigorously expressed in liver tumor and TICs. MAPK6 deficient liver TICs showed impaired self-renewal, and MAPK6 overexpression promoted the self-renewal of liver TICs, revealing the critical role of MAPK6 in liver TICs.

Long noncoding RNAs (LncRNAs) are defined as RNA molecules which are longer than 200 nucleotides in length but can’t code protein [4]. Recent studies defined IncRNAs as critical modulators in various physiological and pathological processes, including tumorigenesis [29, 35]. As for tumorigenesis, IncRNAs are involved in tumor formation, colony formation, metastasis, energy metabolism and so on [17, 32, 37, 39]. LncRNAs can combine with chromatin remodeling complexes (SWI/SNF, NURD, NURF, PRC1/2, and so on) and regulate the transcription of target genes [35]. LncRNAs also interact with signaling proteins and change their stability or activity [32, 36]. Here, we found IncMAPK6 and MAPK6 were vigorously expressed in liver TICs. IncMAPK6 and MAPK6 were involved in the maintenance regulation of liver TICs. IncMAPK6 interacted and recruited RNA polymerase II to MAPK6 promoter to initiate transcription. Moreover, IncMAPK6-MAPK6 pathway serve as a target for liver propagation and TIC clearance.

**Methods**

**Primary samples**
The detailed information of these sample was: #1, early HCC, 61 years old, female, tumor size, 7.2 × 6.3 × 5.2 mm, non-metastasis. #4, advanced HCC, 74 years old, male, tumor size, 7.9 × 5.3 × 4.8 mm, metastasis. #5, advanced HCC, 63 years old, female, tumor size, 6.9 × 6.1 × 4.2 mm, non-metastasis.

**Antibodies and reagents**
Anti-β-actin antibody and DAPI were purchased from Sigma-Aldrich. Anti-MAPK6 and anti-POLR2A antibodies were from Proteintech. PE-CD133 was obtained from MiltenyiBiotec. T7 RNA polymerase and Biotin RNA Labeling Mix were purchased from Roche. The LightShift Chemiluminescent RNA EMSA and Chemiluminescent Nucleic Acid Detection kits were from Thermo Scientific.

**Oncosphere formation**
The oncosphere formation assay was performed as described [40]. Briefly speaking, 5000 HCC cells were cultured in sphere formation medium (N2, B27, 20 ng/ml EGF and 20 ng/ml bFGF, in DMEM/F12) and seeded into Ultra Low Attachment 6-well plates. Two weeks later, oncospheres were counted typical images were taken.

**Tumor propagation and initiating assay**
For tumor propagation, 1 × 10⁶ IncMAPK6 silenced, overexpressed or control cells were injected into BALB/c nude mice, which were satisficed 1 month later and tumors were weighted. For tumor-initiation, 10, 1 × 10², 1×1 0 ³,1 × 1 0 ⁴, and 1 × 10⁵ IncMAPK6 silenced cells or overexpressed cells were injected into 6-week-old BALB/c nude mice. The ratios of tumor-free mice and tumor TIC ratios were calculated 3 months later. For each sample, six mice were used for tumor injection.

**Immunohistochemistry**
Immunohistochemistry (IHC) was performed as described [41]. For IHC, Tris/EDTA buffer was used for antigen retrieval. The samples were detected by HRP substrates and observed with Nikon-EclipseTi microscopy.

**RNA pulldown**
RNA pulldown assay was performed as described [27]. Briefly speaking, biotin-labeled IncMAPK6 transcript was obtained through in vitro transcription, and incubated in sphere lysate. Streptavidin beads were then added for component enrichment, followed by Western blot or silver staining.

**Statistical analysis**
For statistical analysis, one-tailed Student’s t tests were used. P < 0.05 was defined to be statistically significant. Other than denoted, data were shown as means±s.d. *P < 0.05; **P < 0.01; ***P < 0.001. All experiments were repeated at least three times.
Results

MAPK6 was up-regulated in liver tumor and liver TICs

Liver TICs are important for liver tumorigenesis, relapse, metastasis and drug resistance. MAPK signaling pathway is a integration point for multiple biochemical signals. However, the role of MAPK pathway in liver TICs hasn’t been explored. Here we performed a unbiased screening for the expression levels of MAPK components in liver cancers using GSE14520 dataset [23, 26]. Of the MAPK components, MAPK6 is most highly expressed in liver cancer samples (Fig. 1a, b), MAPK6 overexpression levels are related to clinical survival (Fig. 1c). To further examine the high expression of MAPK6 in liver cancer, we detected MAPK6 expression levels with realtime PCR and Western blot. MAPK6 was up-regulated along with liver tumorigenesis (Fig. 1d, e). Of note, MAPK6 expression was also related to cancer severity (Fig. 1d, e).

We then examined MAPK6 expression pattern in liver TICs. We isolated liver TICs through surface marker CD133, and found MAPK6 was highly expressed in liver

![Fig. 1](Image)

**Fig. 1** Overexpression of MAPK6 in liver tumor and TICs. (a) Expression profiles of MAPK components were shown as heatmap. Blue denoted low expression and red denoted high expression. (b) MAPK6 is highly expressed in liver cancers. (c) According to MAPK6 expression, HCC samples were divided into two groups (MAPK6(high) and MAPK6(low)) for Kaplan–Meier survival analysis. (d) MAPK6 expression were examined in 19 peri-tumor samples, 7 early HCC samples (eHCC) and 12 advanced HCC samples (aHCC), and all the results were normalized to the average of peri-tumor expression. (e) Immunohistochemistry of MAPK6 in peri-tumor, eHCC and aHCC. Representative images and indicated ratios were shown. (f, g) MAPK6 mRNA expression in CD133+ liver TICs (f) or oncospheres (g) was examine with realtime PCR. RNA expression levels were normalized to MAPK6 expression in non-TICs. For (b), data were presented as box and whisker plot, boxes represent interquartile ranges (IQR).
TICs (Fig. 1f). We performed sphere formation assay, and also found high expression of MAP6 in oncospheres (Fig. 1g).

**High expression of IncMAPK6 in liver cancer and liver TICs**

We then explored the regulation mechanism of MAPK6 expression. Firstly, we observed MAPK6 locus, and found IncRNA ENST00000561318 (hereafter named IncMAPK6) is a divergent IncRNA of MAPK6 (Fig. 2a). Through Northern blot, IncMAPK6 was also highly expressed in HCC samples (Fig. 2b). We then examined IncMAPK6 expression profile through in situ hybridization (ISH). As shown in Fig. 2c, IncMAPK6 was highly expressed in liver cancer.

We also detected IncMAPK6 expression in liver TICs. We enriched CD133⁺ liver TICs, examined IncMAPK6 expression with realtime PCR, and found increased IncMAPK6 expression in liver TICs (Fig. 2d). We also performed sphere formation assay and found increased IncMAPK6 expression in oncospheres (Fig. 2e). Fluorescence in situ hybridization (FISH) also confirmed the high expression of IncMAPK6 in liver TICs (Fig. 2f) and oncospheres (Fig. 2g). Altogether, IncMAPK6 was highly expressed in liver tumor and TICs.

**LncMAPK6 activated liver TIC self-renewal**

We also detected the role of LncMAPK6 in liver TIC regulation. LncMAPK6 depleted cells were generated for oncosphere formation assay. Sphere formation was inhibited once LncMAPK6 was depleted, indicating the essential role of LncMAPK6 in liver TIC self-renewal (Fig. 3a). We also injected 10, 1 × 10², 1 × 10³, 1 × 10⁴ and 1 × 10⁵ LncMAPK6 depleted cells into BALB/c nude mice for tumor initiation, and found impaired tumor

---

**Fig. 2** LncMAPK6 is overexpressed in liver tumor and TICs. (a) MAPK6 locus was shown. There is a divergent IncRNA (ENST00000561318, termed as IncMAPK6 in this research) in near from MAPK6 locus according to UCSC Genome Browser. (b) IncMAPK6 expression levels were detected using Northern blot. 18S rRNA was a loading control. (c) 19 peri-tumor, 7 eHCC and 12 aHCC were used for in situ hybridization (ISH). Representative photos and indicated ratios were shown. (d) LncMAPK6 expression levels in CD133⁺ liver TICs and CD133⁻ non-TICs were detected by realtime PCR, and non-TIC expression was used for data normalization. (e) Spheres and non-spheres were selected, and LncMAPK6 expression was examined with realtime PCR. (f, g) FISH assay confirmed the high expression of LncMAPK6 in liver TICs (f) and oncospheres (g). Zic2 and CD133 were markers of liver TICs. Scale bars, C, 50 μm; F, 20 μm
initiation (Fig. 3b). The ratios of liver TICs were also decreased upon lncMAPK6 depletion (Fig. 3b). We also found lncMAPK6 was required for the invasion of liver TICs (Fig. 3c). We also silenced lncMAPK6 through antisense oligo (ASO) and performed sphere formation and transwell assays. The results confirmed that lncMAPK6 was required for the self-renewal and invasion of liver TICs (Fig. 3d, e).

To further confirm the role of lncMAPK6 in liver TICs, we then overexpressed lncMAPK6 through CRISPRa strategy, and found lncMAPK6 overexpression promoted the self-renewal of liver TICs (Fig. 3f). Then we injected $10^2$, $10^3$, $10^4$ and $10^5$ lncMAPK6 overexpressed cells for tumor initiation, and found lncMAPK6 overexpression promoted tumor formation (Fig. 3g). Altogether, lncMAPK6 played an important role in the self-renewal of liver TICs.

### LncMAPK6 drove MAPK6 expression

Many lncRNAs participate in the transcription of nearby genes, thus we detected whether lncMAPK6 drove the expression of MAPK6. We examined MAPK6 expression levels with lncMAPK6 depleted cells and found decreased MAPK6 expression upon lncMAPK6 knockdown (Fig. 4a). Western blot also found that lncMAPK6 depletion largely impaired MAPK6 expression (Fig. 4b).
Fig. 4 (See legend on next page.)
On the contrary, lncMAPK6 overexpression promoted the expression of MAPK6 (Fig. 4c). Altogether, lncMAPK6 drove the expression of MAPK6.

Next we detected the role of MAPK6 in liver TICs. MAPK6 knockout cells were constructed and showed impaired sphere formation capacity, indicating that MAPK6 was necessary for liver TIC self-renewal (Fig. 4d). We also performed tumor initiation with gradient MAPK6 knockout cells, and found MAPK6 knockout largely impaired tumor initiation capacity (Fig. 4e). Meanwhile, MAPK6 knockout cells contained decreased ratios of liver TICs (Fig. 4e). Altogether, MAPK6 was essential in liver TIC self-renewal.

We also detected the importance of MAPK6 for lncMAPK6 function. We silenced lncMAPK6 expression in MAPK6 knockout cells, followed by sphere formation. Interestingly, lncMAPK6 had no effect on liver TIC self-renewal upon MAPK6 knockout, revealing the critical function of MAPK6 in lncMAPK6 (Fig. 4f). Similarly, we overexpressed lncMAPK6 in MAPK6 knockout cells and

![Figure 4](See figure on previous page.)

**Fig. 4** LncMAPK6 drove MAPK6 expression. (a) MAPK6 expression in lncMAPK6 depleted cells was detected using three primary samples. (b, c) LncMAPK6-depleted (b) and overexpressed (c) cells were used for MAPK6 examined with immunobloting. CRISPRi-lnc, CRISPRi-lncMAPK6; CRISPRa-lnc, CRISPRa-lncMAPK6. β-actin was a loading control. (d) MAPK6 knockout cells were established and sphere formation assay was performed. Typical images and indicated ratios were shown in middle and right panels, respectively. (e) 10, 1 x 10², 1 x 10³ and 1 x 10⁴ MAPK6 knockout cells were used for tumor formation. (f, g) LncMAPK6 was silenced (f) or overexpressed (g) in MAPK6 knockout cells and lncMAPK6 didn’t participate in liver TIC self-renewal upon MAPK6 was deleted. (h) MAPK6 knockout cells were used for lncMAPK6 knockdown (h) or overexpression (i), followed by transwell assay.

![Figure 5](See figure on previous page.)

**Fig. 5** LncMAPK6 interacted with RNA polymerase II. (a) LncMAPK6 was transcribed in vitro for RNA pulldown, and the denoted band in lncMAPK6 sample was identified as POLR2A. (b) The binding of LncMAPK6 and POLR2A was examined by Western blot. (c) LncMAPK6 truncates were generated (left panels), and incubated with sphere lysates. The interaction between lncMAPK6 truncates and POLR2A was confirmed (right panels). (d) RNA EMSA was performed for the combination between LncMAPK6 and POLR2A. The second truncate of LncMAPK6 was used for RNA EMSA. (e) Oncospheres derived from clinical samples were used for RNA immunoprecipitation (RIP) assay, and enrichment of lncMAPK6 were detected with real-time PCR. GAPDH was a control. (f) The co-localization of LncMAPK6 and POLR2A was confirmed by double FISH assay. Scale bars, 10 μm. (g, h) LncMAPK6 depleted (g) and overexpressed (h) cells were crushed for POLR2A CHIP, followed by detection for MAPK6 promoter enrichment with real-time PCR.
found impaired role of lncMAPK6 (Fig. 4g). Beside sphere formation assay, tumor invasion capacity was also examined. LncMAPK6 had no effect on tumor invasion if MAPK6 was knockout, further confirming the importance of MAPK6 in lncMAPK6 signaling (Fig. 4h, i). Altogether, LncMAPK6 drove liver TIC self-renewal by MAPK6.

**LncMAPK6 recruits RNA polymerase II to MAPK6 promoter**

To investigate the molecular mechanisms of lncMAPK6 in MAPK6 expression and subsequent liver TIC self-renewal, RNA pulldown assay was performed. Mass spectrum was used for protein identification and the interaction between lncMAPK6 and POLR2A was found (Fig. 5a), which was also validated by Western blot (Fig. 5b). LncMAPK6 truncates were also constructed for RNA pulldown. The second region of lncMAPK6 (#2) was required for binding with POLR2A (Fig. 5c). EMSA experiment also confirmed the combination of lncMAPK6 and POLR2A (Fig. 5e). We also examined the physiological interaction of POLR2A and lncMAPK6 with RNA immunoprecipitation (Fig. 5e). Double fluorescence in situ hybridization (double-FISH) was also confirmed the co-localization of lncMAPK6 and POLR2A (Fig. 5f).

POLR2A, a component of RNA polymerase II, plays a fundamental role in transcriptional initiation. Thus we...
explored the role of lncMAPK6-POLR2A interaction in MAPK6 transcription. We found POLR2A combined with MAPK6 promoter in liver TICs, while, their binding was diminished upon lncMAPK6 was depleted (Fig. 5g). On the contrary, lncMAPK6 overexpression largely promoted the binding of POLR2A and MAPK6 promoter (Fig. 5h). Altogether, lncMAPK6 recruited RNA polymerase II to the promoter of MAPK6 to drive its expression.

**LncMAPK6-MAPK6 served as a target for liver TIC clearance**

Finally, we detected the TIC targeting role of lncMAPK6-MAPK6. We examined the tumor propagation capacity of lncMAPK6 depleted cells and lncMAPK6 overexpressed cells, and found lncMAPK6 played an important role in liver tumor propagation (Fig. 6a, b). We also established MAPK6 promoter deleted cells, followed by tumor propagation. MAPK6 promoter or MAPK6 knockout cells also showed impaired propagation (Fig. 6c). We performed immunohistochemistry assay, and the results showed impaired expression of MAPK6 in lncMAPK6 knockout or MAPK6 promoter deleted tumors, validating the role of lncMAPK6 in MAPK6 expression (Fig. 6d). We obtained tumor cells and found lncMAPK6-MAPK6 pathway was required for the proliferation of tumor cells (Fig. 6e). Meanwhile, lncMAPK6-MAPK6 inhibition also induced a decreased numbers of liver TICs, indicating that lncMAPK6-MAPK6 can be used for liver TIC clearance (Fig. 6f). Taken together, lncMAPK6-MAPK6 blockade inhibited the self-renewal and maintenance of liver TICs.

**Discussion**

Wnt/β-catenin, Notch and Hedgehog signaling pathways are well-explored pathways in liver TIC self-renewal. All these signaling pathways are finely regulated. Wnt/β-catenin activation is largely modulated by β-catenin stability or activity [7, 10, 22]. Notch activation is regulated by Notch cleavage and nuclear translocation [40]. Here we found MAPK6, a component of MAPK signaling pathway, is involved in the self-renewal of liver TICs. What’s more, MAPK6 is also precisely regulated by lncMAPK6. LncMAPK6 located onto the MAPK6 promoter and recruited RNA polymerase II to MAPK6 promoter, which further activate the transcription activation of MAPK6.

LncRNAs play important roles in many biological processes [25]. Here we found a lncRNA drove the self-renewal of liver TICs through MAPK6. Interestingly, lncMAPK6 is a divergent lncRNA of MAPK6. Divergent lncRNAs are transcribed in the opposite direction from nearby genes [12]. Divergent lncRNAs, often modulate their nearby genes in cis, are positively-related to their nearby genes [12]. As a divergent lncRNA of MAPK6, lncMAPK6 was co-expressed with MAPK6 in liver tumor and TICs. LncMAPK6 regulated the expression of MAPK6 through transcriptional activation. There are several lncRNAs involved in MAPK modulation. MALAT1 drove the proliferation and metastasis of gallbladder cancer cells through MAPK signaling [1]. DBH-AS1 and URHC are required for the proliferation and survival of hepatocellular carcinoma by MAPK activation [13, 18]. Here we found lncMAPK6 promoted MAPK6 expression to drive liver TIC self-renewal, revealing the role of MAPK signaling in liver TIC self-renewal and adding a new layer for MAPK6 transcriptional regulation.

As we know, It is impossible that a lncRNA only target one gene. However, we found lncMAPK6 had impaired role upon MAPK6 was deleted, indicating lncMAPK6 exerted its role mainly through MAPK6. We think several reasons can explain this result. 1. Some lncRNAs may locate at particular subcellular position, and the location limited the number of their target genes. 2. lncRNA targeted some other genes, but these genes weren’t required for the self-renewal of liver TICs; 3. Some lncRNAs participated in the transcriptional regulation through lncRNA transcription process but not lncRNAs themself [31]. The process of lncRNA can activate the transcription of their nearby genes. Meanwhile, our results indicated that MAPK6 participated in the self-renewal of liver TICs, but the molecular mechanism of MAPK6 function is still unclear, which need further investigation. Altogether, lncMAPK6 drove the self-renewal of liver TICs through MAPK6 expression. LncMAPK6-MAPK6 pathway can be used for liver TIC targeting.

**Conclusion**

MAPK6 was the most highly expressed MAPK component in liver cancer and liver TICs and lncMAPK6 participated in the transcriptional regulation of MAPK6 in cis. This work revealed the importance role of MAPK signaling in liver TIC self-renewal and added a new layer for liver TIC and MAPK6 expression regulation.

**Acknowledgements**

The authors thank Yueming He (Department of Abdominal Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University) for experimental supports.

**Funding**

This work was supported by science and technology projects of Guangdong province (2017A020211031, 2016ZC0145), science and technology projects of Guangzhou Medical University (201624), the National Natural Science Foundation of China (81673206) and science and technology projects of Guangzhou city (201508020262), Medical Scientific Research Foundation of Guangdong province (A2015243).

**Availability of data and materials**

All data and materials can be provided upon request (email nhaiaejq1465@126.com or sdf1984365@126.com).

**Authors’ contributions**

GH and HJ performed experiments, analyzed data and wrote the paper; YH, LY, WX, YL, ML and BS performed some experiments and analyzed data; XZ and ZJ initiated the study, designed experiments and wrote the paper. All authors read and approved the final version of the manuscript.
Ethics approval and consent to participate
Primary hepatocarcinoma samples were obtained from the Fifth Affiliated Hospital of Guangzhou Medical University and Guangdong General Hospital with informed consent, according to the Institutional Review Board approval. HCC samples were recorded by the obtained time, and some samples (1#, 4# and 5#) with sphere formation capacity were selected for most of the assays.

Consent for publication
The author agree for publication.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of general surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong Sheng, China. 2Department of Abdominal Oncology, The Fifth Affiliated Hospital of Guangzhou University, Guangdong Sheng, China. 3Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangdong Sheng, China.

Received: 2 April 2018 Accepted: 27 April 2018
Published online: 15 May 2018

References
1. Aderem A. The MARCKS brothers: a family of protein kinase C substrates. Cell. 1992;71:175–6.
2. Aderem A. The MARCKS family of protein kinase-C substrates. Biochem Soc Trans. 1995;23:587–91.
3. Anderson KM, Anderson DM, McAnally JR, Shelton JM, Bassel-Duby R, Olson EN. Transcription of the non-coding RNA upperhand controls Hand2 expression and heart development. Nature. 2016;539:433–6.
4. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298–307.
5. Blackshear PJ. The MARCKS family of cellular protein kinase substrates. J Biol Chem. 1993;268:15101–4.
6. Carballo E, Colomer D, Vives Corrons JL, Blackshear PJ, Gil J. Phosphorylation of the MARCKS family of protein kinase C substrates. Biochem Soc Trans. 1992;20:587–91.
7. Chen ZZ, Huang L, Wu YH, Zhai WJ, Zhu PP, Gao YF. LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-mediated Sox4 transcriptional activation. Oncogene. 2018;37.
8. Chen ZZ, Huang L, Wu YH, Zhai WJ, Zhu PP, Gao YF. LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-mediated Sox4 transcriptional activation. Oncogene. 2018;37.
9. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma harbors human cancer stem cell-like properties. Hepatology. 2006;44:240–51.
10. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192–205.
11. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takuchi D, Hatanaka H, Nagano H, Barnard GF, Doki Y, Mori M. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120:3236–29.
12. He YL, Zhang LF, Chen ZZ, Li YF, Zhang J, Li YF. Enhanced chemotherapy efficacy by co-delivery of shABC2G and doxorubicin with a pH-responsive charge-reversible layered graphene oxide nanocomplex. J Mater Chem B. 2015;3:6462–72.
13. Herget T, Brooks SF, Broad S, Rozenburg E. Relationship between the major protein kinase C substrates acidic 80-kDa protein-kinase-C substrate (80K) and myristoylated alanine-rich C-kinase substrate (MARKS). Members of a gene family or equivalent genes in different species. Eur J Biochem. 1992;209:7–14.
14. Hidaka S. Conflicting effects by antibodies against connexin36 during the action of intracellular cyclic-AMP onto electrical synapses of retinal ganglion cells. J Integr Neurosci. 2016;15:571–91.
15. Ho MM, Ng AV, Lam S, Hung JY, Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4257–33.
16. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275–91.
17. Leucci E, Vendramini R, Spinazzi M, Laurette P, Fiers M, Wouters J, Radaelli E, Eckerman S, Leonelli C, Vanderheyden K, Rogiers A, Hermans E, Baetsen P, Aerts S, Amant F, Van Aelst S, van den Oord J, de Strooper B, Davidson I, Lafontaine DL, Gevaert K, Vandecompele J, Mestdagt P, Marine JC. Melanoma addiction to the long non-coding RNA SAMMSON. Nature. 2016;531:518–22.
18. Li J, Aderem A, MacMARKS, a novel member of the MARCKS family of protein kinase C substrates. Cell. 1992;70:791–801.
19. Liu BY, Ye BQ, Yang LL, Zhu XX, Huang GL, Zhu PP, Du Y, Yu W, JIY, Qin XW, Chen RS, Tian Y, Fan ZS. Long noncoding RNA Incm2ds1 is required for IL-3 maintenance following initiation of ZIPf2p29 expression. Nat Immunol. 2017;18:499–508.
20. Ma S, Chan KW, Lu L, Lee TKW, Wo YHJ, Ng IIL, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:542–56.
21. Ma S, Chan KW, Lee TKW, Tang KH, Wo YHJ, Zheng BJ, Guan XY. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008;6:1146–53.
22. MacDonald BT, Tamai K, He X, Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:59–69.
23. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483–7.
24. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8:486–98.
25. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:29–41.
26. Prendergast JR, Chinnaian AM. The emergence of IncRNAs in cancer biology. Cancer Discov. 2011;1:391–407.
27. Ribba NB, Haines GM, Emerson CP. Protein kinase C delta and mitogen-activated protein kinase/extracellular signal-regulated kinase-1 control Glu activation in hedgehog signaling. Cancer Res. 2006;66:6399–45.
28. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun ZT, Tang ZY, Qin LX, Wang XW. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:20102–2.
29. Shimokawa M, Ohta Y, Nishikori S, Matano M, Takano A, Fujii M, Date S, Sugimoto S, Kainu T, Sato T. Visualization and targeting of LGR5+ human colon cancer stem cells. Nature. 2017.
30. Takebe N, Miele L, Harris PN, Jeong W, Bando H, Kahn M, Yang S, Yew SP. Targeting notch, hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445–64.
31. Tam WS, Lu HH, Bulikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Kral JA, Bierle B, Guo WX, Chen X, Liu XS, Brown M, Lim B, Weinberg RA. Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013;24:347–64.
32. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Eyckerman S, Leonelli C, Vanderheyden K, Hermans E, Baatsen P, Marahrens Y, Kawakami Y, Bagchi A. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512:822–6.
33. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.
34. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:171–8.
35. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–14.
36. Wang P, Xue YQ, Han YM, Lin L, Wu C, Xu X, Jiang ZP, Xu JF, Liu QY, Cao XT. The STAT3-binding long noncoding RNA Inc-DC controls human dendritic cell differentiation. Science. 2014;344:310–3.
37. Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol Cell. 2014;53:88–100.
38. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ng P, Chu PKW, Lam CT, Pooh RTP, Fan ST. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153–66.
39. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, Wang SB, Wang YZ, Yang Y, Yang N, Zhou WP, Yang GS, Sun SH. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis Cascade in hepatocellular carcinoma. Cancer Cell. 2014;25:666–81.

40. Zhu P, Wang Y, Du Y, He L, Huang G, Zhang G, Yan X, Fan Z. C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling. Nat Commun. 2015;6:7122.

41. Zhu P, Wang Y, He L, Huang G, Du Y, Zhang G, Yan X, Xia P, Ye B, Wang S, Hao L, Wu J, Fan Z. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. J Clin Invest. 2015;125:3795–808.

42. Zhu P, Wang Y, Huang G, Ye B, Liu B, Wu J, Du Y, He L, Fan Z. Lnc-beta-Caten elicits EZH2-dependent beta-catenin stabilization and sustains liver CSC self-renewal. Nat Struct Mol Biol. 2016;23:631–9.

43. Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B, Du Y, Gao G, Tian Y, He L, Fan Z. LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. Nat Commun. 2016;7:13608.

44. Zhu PP, Fan ZS. Cancer stem cell niches and targeted interventions. Prog Biochem Biophys. 2017;44:697–708.